Publication:
Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis

Simple item page
dc.contributor.authorSoysal, PINAR
dc.contributor.authorIsik, Ahmet Turan
dc.contributor.authorStubbs, Brendon
dc.contributor.authorSolmi, Marco
dc.contributor.authorVolpe, Marco
dc.contributor.authorLuchini, Claudio
dc.contributor.authorD'Onofrio, Grazia
dc.contributor.authorPilotto, Alberto
dc.contributor.authorManzato, Enzo
dc.contributor.authorSergi, Giuseppe
dc.contributor.authorSchofield, Patricia
dc.contributor.authorVeronese, Nicola
dc.contributor.institutionauthorSOYSAL, PINAR
dc.date.accessioned2021-01-20T20:59:17Z
dc.date.available2021-01-20T20:59:17Z
dc.date.issued2016-12-01T00:00:00Z
dc.description.abstractWe conducted a systematic review and meta-analysis investigating the influence of acetylcholinesterase inhibitors (AChEIs) therapy on nutritional status and weight across observational and interventional studies. Two authors searched major electronic databases from inception until 10/14/2015 for longitudinal, open-label and randomised double-blind placebo controlled (randomised controlled trials (RCTs)) studies of AChEIs in patients with dementia reporting nutritional status outcome data. Out of 3551 initial hits, 25 studies (12 open-label trials, 9 RCTs and 4 longitudinal studies) including 10 792 patients with dementia were metaanalysed. In longitudinal studies (median follow-up 6 months), a significant cumulative incidence of weight loss between baseline and follow-up evaluation was observed (studies= 2; 5%; 95% CI 1% to 34%, p< 0.0001; I2= 95%). These findings were confirmed in open-label trials (6%; 95% CI 4% to 7%, p< 0.0001; I-2= 78%). In 9 RCTs (median followup 5 months), those taking AChEIs more frequently experienced weight loss than participants taking placebo (OR= 2.18; 95% CI 1.50 to 3.17, p< 0.0001; I-2= 29%). AChEIs therapy contributes to weight loss in patients with dementia, with a 2-fold increased risk observed in the meta-analysis of RCTs. Clinicians should carefully consider the benefit and risk of prescribing AChEIs. Nutritional status should be routinely evaluated in patients with dementia treated with AChEIs.
dc.identifier.citationSoysal P., Isik A. T. , Stubbs B., Solmi M., Volpe M., Luchini C., D-Onofrio G., Pilotto A., Manzato E., Sergi G., et al., -Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis-, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, cilt.87, ss.1368-1374, 2016
dc.identifier.doi10.1136/jnnp-2016-313660
dc.identifier.scopus84973294726
dc.identifier.urihttp://hdl.handle.net/20.500.12645/28062
dc.identifier.wosWOS:000389472700259
dc.titleAcetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis
dc.typeArticle
dspace.entity.typePublication
local.avesis.ida373b9af-ae53-4323-a839-b901840c0eb3
local.publication.goal16 - Barış, Adalet ve Güçlü Kurumlar
local.publication.isinternational1
relation.isAuthorOfPublication0e36986e-d71d-4579-a395-877af097ade5
relation.isAuthorOfPublication.latestForDiscovery0e36986e-d71d-4579-a395-877af097ade5
relation.isGoalOfPublication7e7ce1dc-9556-4fa2-b604-c2ba181d38b9
relation.isGoalOfPublication.latestForDiscovery7e7ce1dc-9556-4fa2-b604-c2ba181d38b9
Files
Collections
Silinecekler